Phaseline

Companies › Graegis Pharmaceuticals

Graegis Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GR1014-CG 2.4%
Topical amifostine thiol, a cytoprotective agent that protects skin from radiation-induced
–Phase 2Radiodermatitis; Acute–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07192588GR1014-CG 2.4%Phase 2Radiodermatitis; AcuteOncologySep 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.